Back to top

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

Wedbush notes that Vertex Pharmaceuticals (VRTX) agreed to acquire Crinetics Pharmaceuticals (CRNX) for $85/share in cash. Crinetics now trades ess...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Ascendis Pharma A/S (ASND)

BioCryst Pharmaceuticals, Inc. (BCRX)

Crinetics Pharmaceuticals, Inc. (CRNX)

Vertex Pharmaceuticals Incorporated (VRTX)